Overview

Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

Status:
Recruiting

Trial end date:
2038-12-01

Target enrollment:

Participant gender:

Summary

The primary objective is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL) in Cohort 3 of this study.

Phase:

Phase 2

Details

Lead Sponsor:

Kite, A Gilead Company

Treatments:

Cyclophosphamide
Fludarabine